We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    Buntanetap
Previous Study | Return to List | Next Study

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05357989
Recruitment Status : Recruiting
First Posted : May 3, 2022
Last Update Posted : September 21, 2022
Sponsor:
Collaborator:
TFS Trial Form Support
Information provided by (Responsible Party):
Annovis Bio Inc.

Brief Summary:

The purpose of this study is to measure safety and efficacy of buntanetap capsules compared with placebo capsules in participants with early PD.

Study details include:

  • The study duration will be up to 7-8 months.
  • The double-blind treatment duration will be up to 6 months.
  • There will be 5 in-clinic visits and 7 phone calls

Condition or disease Intervention/treatment Phase
Parkinson's Disease, Idiopathic Drug: Buntanetap Drug: Placebo Phase 3

Detailed Description:

450 early Parkinson's Disease (PD) patients will be randomized to 10mg, 20 mg of Buntanetap or placebo. They will undergo a Screening Visit, and if they provide informed consent and are considered eligible per the inclusion and exclusion criteria, will proceed to participate in the treatment period. Randomized participants will visit the clinic for the first-time dosing in clinic with administration of 10 mg or 20mg of Buntanetap or Placebo, followed by an at home dosing period of 6 months, with daily administration of 10 mg or 20mg of Buntanetap or Placebo. Participants will be required to visit clinics 1 month, 2 months, 3 months, and 6 months (end-of-trial), where they will undergo study procedures that include safety assessments (AE and concomitant medication monitoring, 12-lead ECGs, clinical laboratory testing, vital signs assessments, and physical examinations) and psychometric tests (MDS-United Parkinson's Disease Rating Scale (MDS-UPDRS), Clinical Global Impression of Severity (CGIS), Wechsler Adult Intelligence Scales (WAIS), Mini-Mental State Examination (MMSE)) and Participant Global Impression of Change (PGIC). At the end of blood sampling, the subjects will need to stay for a minimum of 1 hour of observation. After all end-of-study procedures are complete, the subject will be discharged to home. A 24-hour follow-up call will occur after all clinical visits to assess the participants current condition and if there are any additional adverse events to report.

Buntanetap has shown to improve PD subjects' mobility. MDS-UPDRS sum of score of Part II + Part III and Total score of all four parts will be measured to assess its improvement on PD subjects daily living, mobility and complications. PGIC will also be measured to assess its effect.

Buntanetap has shown to reduce inflammation and preserve axonal integrity and synaptic functions as well as neurotoxic proteins in previous Phase 2a studies. In this study we plan to measure plasma GFAP, NFL and potentially TDP43.

Reports of adverse events (AEs) and serious adverse events (SAEs) during exposure to buntanetap will be collected to evaluate if there are any significant clinical safety issues for the study population. Extensive clinical and laboratory safety data already exist for buntanetap; therefore, these safety measures will be sufficient in the proposed study.

For clinical, functional, and cognitive assessment measures, The subjects will be administered the Hoehn & Yahr and the MMSE for determination of inclusion into the study. The MDS-UPDRS and PGIC will be administered for subjects' movement and daily function. The Coding subtest from the WAIS 4th edition will serve as a sensitive measure of Central Nervous System (CNS) dysfunction. MMSE will also be measured to assess subjects' cognitive change.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 450 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A 6-month Prospective, Randomized, Double-blind, Placebo-controlled Clinical Trial Investigating the Efficacy, Safety, and Tolerability of Two Different Doses of Buntanetap or Placebo in Patients With Early Parkinson's Disease
Actual Study Start Date : August 3, 2022
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : December 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 10 mg Buntanetap,
Buntanetap 10 mg oral capsule with daily administration for a period of 6 months
Drug: Buntanetap
HPMC (vegetarian source) capsule shells
Other Names:
  • Posiphen Tartrate
  • ANVS401

Experimental: 20 mg Buntanetap
Buntanetap 20 mg oral capsule with daily administration for a period of 6 months
Drug: Buntanetap
HPMC (vegetarian source) capsule shells
Other Names:
  • Posiphen Tartrate
  • ANVS401

Placebo Comparator: Placebo
Placebo oral capsule with daily administration for a period of 6 months
Drug: Placebo
HPMC (vegetarian source) capsule shells




Primary Outcome Measures :
  1. MDS-Unified Parkinson's Disease Rating Scale Part II+III (OFF-state) [ Time Frame: From baseline to end of trial (6 months) ]

    The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a 42-item rating scale designed to assess Parkinson's disease-related disability and impairment. The scale comprises four parts: Part I evaluates mentation, behaviour, and mood symptoms; Part II evaluates activities of daily living (ADL); Part III evaluates motor function; and Part IV evaluates complications of dopaminergic therapy.

    The total score is the sum of the subscale scores for Parts I to III and ranges from 0 (no disability) to 176 (total dependence). This assessment will be based on a change in the sum of the score from the Activities of Daily Living (ADL) Scale (Part II) and Motor Examination in the Unified Parkinson's Disease Rating Scale (Part III), from Baseline to the End of Trial.


  2. Safety and tolerability as accessed by physical examinations, vital signs, clinical laboratory test results, electrocardiogram findings, adverse events (AEs) leading to study discontinuation, drug related AEs, severity of AEs and AEs. [ Time Frame: From consent to end of trial (up to 8 months) ]
    Safety and tolerability as accessed by physical examinations, vital signs, clinical laboratory test results, electrocardiogram findings, adverse events (AEs) leading to study discontinuation, drug related AEs, severity of AEs and AEs. The frequencies of adverse events, serious adverse events, and laboratory abnormalities between the participants across the treatment groups will be compared.


Secondary Outcome Measures :
  1. MDS-Unified Parkinson's Disease Rating Scale Total Score (OFF-state) [ Time Frame: Baseline, 2 months and 6 months visits ]
    The MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) is a 42-item rating scale designed to assess Parkinson's disease-related disability and impairment. The scale comprises four parts: Part I evaluates mentation, behaviour, and mood symptoms; Part II evaluates activities of daily living (ADL); Part III evaluates motor function; and Part IV evaluates complications of dopaminergic therapy. The total score is the sum of the subscale scores for Parts I to III and ranges from 0 (no disability) to 176 (total dependence).

  2. Percentage of Responders with "Much Improved" or "Very Much Improved" on Participant Global Impression of Change (ON-state) [ Time Frame: Baseline, 2 months and 6 months visits ]
    The participant global impression of change (PGIC) is a participant-reported outcome. The qualitative assessment of meaningful change will be determined by the participant in response to the question, "Compared to your condition at the beginning of treatment, how much has your condition changed?" Scores are 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; and 7=very much worse. Percentage of responders with much improved and very much improved on PGIC scale will be assessed. PGIC will be taken at home while the subject is during ON-state (with their standard of care for Parkinson disease).

  3. Change on Clinical Global Impression of Severity (CGIS) (OFF-state) [ Time Frame: Baseline, 1 month, 2 months, 3 months, and 6 months visits ]
    The clinical global impressions scale on the severity of movement impairment as assessed by the site rater. Site raters will be asked: Considering your total clinical experience with the Parkinson disease population, how ill is the patient at this time? Answers were based on a 0-7 scale, with 1=not assessed, 2= very mild, 3= mild, 4= moderate, 5= moderate severe, 6= severe, 7=extremely severe.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of idiopathic Parkinson Disease according to MDS Clinical Diagnostic Criteria for Parkinson's Disease.
  2. H&Y score =1, 2 or 3 during ON-state & OFF-state <2hrs per day.
  3. Male or female aged 40 - 85 years.
  4. MMSE score between the range of 22-30 during screening visit (ON-state) and subjects can live independently without a caregiver.
  5. Female subjects of childbearing potential* must have a negative serum or urine pregnancy test at Screening, must be non-lactating and must agree to use a highly effective method of contraception (i.e., a method resulting in a failure rate of less than 1% per year when used consistently and correctly) during the trial and for 4 weeks after the last dose of trial treatment, such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion
    • Vasectomized partner (a vasectomized partner is a highly effective contraception method provided that the partner is the sole male sexual partner of the participant, and the absence of sperm has been confirmed. If not, an additional highly effective method of contraception should be used)
    • Sexual abstinence (sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study and the preferred and usual lifestyle of the participant) *Non-childbearing potential includes surgically sterilized or postmenopausal with no menstrual bleeding for at least one year prior to study start.
  6. Male subjects must be sterile or sexually inactive or agree not to father a child during the study and one month after the last dose of study medication and must agree to use a barrier method for contraception. Female partners of male subject must adopt a highly effective method of contraception with a failure rate of less than 1% per year when used consistently and correctly such as:

    • Oral, intravaginal, or transdermal combined (estrogen plus progestogen) hormonal contraception associated with inhibition of ovulation
    • Oral, injectable, or implantable progestogen-only hormonal contraception associated with inhibition of ovulation
    • Intrauterine device (IUD)
    • Intrauterine hormone-releasing system (IUS)
    • Bilateral tubal occlusion 6. Female participants will be given a urine pregnancy test at the screening visit for which they should test negative.
  7. General cognition and functional performance sufficiently preserved that the subject can provide written informed consent.
  8. No evidence of current suicidal ideation or previous suicide attempt in the past month as evaluated in the Columbia Suicide Severity Rating Scale.
  9. Stability of permitted medications prior to screening for at least 4 weeks.
  10. At screening subjects do not need to but may be on the following medication:

    • Standard of Care anti-parkinsonian medication
    • Anticonvulsant medications used for epilepsy or mood stabilization, neuropathic pain indications
    • Mood-stabilizing psychotropic agents, including, but not limited to, lithium.
  11. Adequate visual and hearing ability (physical ability to perform all the study assessments).
  12. Good general health with no disease expected to interfere with the study.
  13. Subjects previously exposed to buntanetap can still be included in the study after a 28- day wash out period.

Exclusion Criteria:

  1. Has a history of a psychiatric disorder such as schizophrenia, bipolar disorder or major depression according to the criteria of the most current version of the Diagnostic and Statistical Manual of Mental Disorders (DSM). Mild depression or history of depression that is stable on treatment with a SSRI or SNRI medication at a stable dose is acceptable.
  2. History of a seizure disorder, if stable on medication is acceptable.
  3. Has a history or current evidence of long QT syndrome, Fridericia's formula corrected QT (QTcF) interval ≥ 475ms, or torsades de pointes.
  4. Has bradycardia (<50 bpm) or tachycardia (>100 bpm) on the ECG at screening.
  5. Has uncontrolled Type-1 or Type-2 diabetes. A subject with HbA1c levels up to 7.5% can be enrolled if the investigator believes the subject's diabetes is under control.
  6. Has clinically significant renal or hepatic impairment.
  7. Has any clinically significant abnormal laboratory values. Subjects with liver function tests (aspartate aminotransferase [AST] or alanine aminotransferase [ALT]) greater than twice the upper limit of normal will be excluded.
  8. Is at imminent risk of self-harm, based on clinical interview and responses on the C SSRS, or of harm to others in the opinion of the Investigators. Subjects must be excluded if they report suicidal ideation with intent, with or without a plan or method (e. g. positive response to Items 4 or 5 in assessment of suicidal ideation on the C SSRS) in the past 2 months, or suicidal behavior in the past 6 months.
  9. Has cancer or has had a malignant tumor within the past year, except subjects who underwent potentially curative therapy with no evidence of recurrence. (Subjects with stable untreated prostate cancer or skin cancers are not excluded).
  10. Alcohol / Substance use disorder, moderate to severe, in the last 5 years according to the most current version DSM.
  11. Participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 60 days prior to the start of screening. The end of a previous investigational trial is the date the last dose of an investigational agent was taken, or five half-lives of the investigational drug, whichever is greater.
  12. Subjects with learning disability or developmental delay.
  13. Subjects whom the site PI deems to be otherwise ineligible.
  14. Subjects with a known allergy to the investigational drug or any of its components.
  15. Subject is currently pregnant, breast-feeding and/or lactating.
  16. Subject is currently taking CYP3A4 inhibitors and/or inducers.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05357989


Contacts
Layout table for location contacts
Contact: Melissa A Gaines 610-727-3722 gaines@annovisbio.com
Contact: Cheng Fang, PhD (610) 727-3987 fang@annovisbio.com

Locations
Show Show 44 study locations
Sponsors and Collaborators
Annovis Bio Inc.
TFS Trial Form Support
Layout table for additonal information
Responsible Party: Annovis Bio Inc.
ClinicalTrials.gov Identifier: NCT05357989    
Other Study ID Numbers: ANVS-22001
First Posted: May 3, 2022    Key Record Dates
Last Update Posted: September 21, 2022
Last Verified: September 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Annovis Bio Inc.:
Parkinson's
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Phenserine
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs